Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Clin Cancer Res. 2014 Nov 25;21(2):286–294. doi: 10.1158/1078-0432.CCR-14-1790

Figure 1. IFN-γ ELISPOT assays on each of vaccine-targeted antigens in Cohorts 1 and 3.

Figure 1

Time course of glioma-associated antigen epitope-specific T-cell responses evaluated by IFN-γ enzyme-linked immunosorbent spot (ELISPOT) analyses in 11 and 9 patients in Cohorts 1 (upper panels) and 3 (lower panels), respectively, who received at least 5 vaccinations. The Week 0 spot numbers are included and post-vaccine spot numbers are not subtracted by Week 0 spot numbers.